Compare Neurocrine Biosciences Inc (NBIX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs ProShares Ultra Gold ETF — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while ProShares Ultra Gold ETF trades at $46.21 (market cap $716.59M). The key difference: Neurocrine Biosciences Inc is far larger — about 20× ProShares Ultra Gold ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and ProShares Ultra Gold ETF for 23 Days on average.
| NBIX | UGL | |
|---|---|---|
Market Cap | $14.36B | $716.59M |
Volume | 1,237,180 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.50 | $85.62 |
52-Week Low | $123.10 | $42.79 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
UGL shares are trading at $44.43, down 3.29% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $45-$46 with support at $43-$44. Recent market sentiment reflects concerns about gold's performance amid rising Treasury yields and Federal Reserve policy uncertainty, creating headwinds for gold-related equities.
The stock's outlook remains challenged by macroeconomic pressures on gold prices, though potential Fed policy shifts could provide catalysts. Key risks include persistent high yields and dollar strength, while opportunities exist if inflation concerns reignite safe-haven demand. Investors should monitor Fed guidance and gold price trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
